Cagrilintide + Semaglutide
This drug combination is being studied clinically. An arbitrary catalogue blend is not automatically the CagriSema trial product.
Components listed in the catalogue
A blend name is not a standardized formula. Ingredients and ratios may vary by product; evidence on individual compounds does not establish the blend’s effects.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Brand or blend identity
The name describes a source-specific product or mixture, not a standardized single substance.
This blend or trade name denotes only the product- and source-specific composition described by the cited catalogue; other products may differ. This drug combination is being studied clinically. An arbitrary catalogue blend is not automatically the CagriSema trial product.
Research areas
Evidence matrix
- Molecular identity
- Product- or blend-specific
This blend or trade name denotes only the product- and source-specific composition described by the cited catalogue; other products may differ. This drug combination is being studied clinically. An arbitrary catalogue blend is not automatically the CagriSema trial product.
- Human research
- Strong
- Replication
- Single research group
- Clinical endpoints
- Symptom- or function-related
- Safety
- Limited characterization
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
Catalogue composition
The cited catalogue lists the components named in this profile together under this blend name.
- PeptideDosages: Cagrilintide + Semaglutide composition listingCatalogue / composition2026
Peptide Dosages
Accessed:
Catalogue or composition source — not a study
Published trials
REDEFINE 1 and the 2026 REIMAGINE 1, 2 and 3 publications studied defined CagriSema trial products; a catalogue blend is not automatically one of those products.
- Coadministered cagrilintide and semaglutide in adults with overweight or obesityHuman study2025
Garvey WT et al.
Accessed:
- CagriSema in early type 2 diabetes: REIMAGINE 1 phase 3aHuman study2026
Aroda VR et al.
Accessed:
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyHuman study2026
Buse JB et al.
Accessed:
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyHuman study2026
Rosenstock J et al.
Accessed:
REDEFINE 4
According to the manufacturer, the studied CagriSema product missed its non-inferiority endpoint versus tirzepatide.
- REDEFINE 4 headline resultsManufacturer information2026
Novo Nordisk A/S
Accessed:
Research gaps
- ·CagriSema remains investigational. Long-term safety and regulatory benefit–risk review remain outstanding; the data do not validate self-mixed formulations.
Mechanism
The combination targets amylin and GLP-1 pathways. Trial findings concern the defined investigational product.
- Coadministered cagrilintide and semaglutide in adults with overweight or obesityHuman study2025
Garvey WT et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Reported adverse effects
- ·Trials primarily reported gastrointestinal adverse events. No approved CagriSema prescribing information with a final safety assessment is available.
Contraindications and warnings
- ·Component contraindications require individual assessment. This does not replace a safety assessment of the combination.
Interactions
- ·Missing blend studies must not be interpreted as absence of interactions.
Research gaps
- ·CagriSema remains investigational. Long-term safety and regulatory benefit–risk review remain outstanding; the data do not validate self-mixed formulations.
- Coadministered cagrilintide and semaglutide in adults with overweight or obesityHuman study2025
Garvey WT et al.
Accessed:
- CagriSema in early type 2 diabetes: REIMAGINE 1 phase 3aHuman study2026
Aroda VR et al.
Accessed:
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyHuman study2026
Buse JB et al.
Accessed:
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyHuman study2026
Rosenstock J et al.
Accessed:
Sources
Sources checked: · Version 3
- PeptideDosages: Cagrilintide + Semaglutide composition listingCatalogue / composition2026
Peptide Dosages
Accessed:
Catalogue or composition source — not a study
- Coadministered cagrilintide and semaglutide in adults with overweight or obesityHuman study2025
Garvey WT et al.
Accessed:
- CagriSema in early type 2 diabetes: REIMAGINE 1 phase 3aHuman study2026
Aroda VR et al.
Accessed:
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyHuman study2026
Buse JB et al.
Accessed:
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyHuman study2026
Rosenstock J et al.
Accessed:
- REDEFINE 4 headline resultsManufacturer information2026
Novo Nordisk A/S
Accessed: